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Abstract
Protein kinases are fundamental components of diverse signaling pathways, including immune cells.
Their essential functions have made them effective therapeutic targets. Initially, the expectation was
that a high degree of selectivity would be critical; however, with time, the use of “multikinase”
inhibitors has expanded. Moreover, the spectrum of diseases in which kinase inhibitors are used has
also expanded to include not only malignancies but also immune-mediated diseases. At present,
thirteen kinase inhibitors have been approved in the United States, all for oncologic indications.
However, there are a growing number of molecules, including several Janus kinase inhibitors, that are
being tested in clinical trials for autoimmune diseases such as rheumatoid arthritis, psoriasis and
inflammatory bowel diseases. It appears likely that this new class of immunomodulatory drugs will
have a major impact on the treatment of immune-mediated diseases in the near future.
Introduction
Work over the last 20 years has firmly established that
reversible protein phosphorylation is a fundamental
mechanism of cell signaling. Protein kinases, also termed
phosphotransferases, are the enzymes that catalyze the
transfer of the γ phosphate of a purine nucleotide
triphosphate (i.e. ATP and GTP) to the hydroxyl groups
of their protein substrates. Importantly, many of the
major classes of receptors that trigger immune cell
activation are linked to protein phosphorylation and
physically associate with kinases. In fact, the first event in
T cell receptor (TCR), B cell receptor (BCR), NK (natural
killer) and Fc receptor signaling is phosphorylation of
receptor subunits on tyrosine residues. Likewise, cyto-
kine receptors, especially Type I/II cytokine receptors,
signal directly by activating kinases, which phosphor-
ylate receptor subunits and thereby initiate signaling.
This has led to the idea that blocking kinases may be an
effective way to block immune cell activation and, in
turn, treat autoimmune disease. Multiple kinase inhibi-
tors are now in clinical trials for rheumatoid arthritis,
inflammatory bowel disease, psoriasis and other
diseases. This is surely an area that will expand in the
next few years, so it is appropriate to briefly review some
of the key issues.
Kinases: the first step in immune cell signaling
There are 518 kinases in the human genome, divided
into eight major groups. The first step in signaling by
multi-chain immune recognition receptors, which
include the TCR, BCR, Fc receptors and others, is tyrosine
phosphorylation of the receptor itself and associated
adapter molecules like LAT (linker for activation of
T cells). This is mediated initially by Src family protein
tyrosine kinases, followed by kinases such as Syk (spleen
tyrosine kinase) or Zap-70, Tec family PTKs and later by
serine-threonine kinases, such as mitogen activated
protein kinases (MAPKs) and protein kinase C (PKC)
family (see Figure 1). Initial protein phosphorylation
ultimately links membrane events to calcium modula-
tion, cytoskeletal rearrangement, gene transcription and
other canonical features of lymphocyte action. Cytokines
that use Type I and II cytokine receptors signal via the
activation of receptor-associated Janus kinases (Jaks).
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growth factor family cytokines, bind to receptors with
intrinsic tyrosine or serine-threonine kinase properties
respectively. Receptors for cytokines such as interleukin
(IL)-1 and tumor necrosis factor (TNF) are not them-
selves directly associated with kinases, but they too link
to downstream kinase cascades.
Where it all started
Since all protein kinases bind ATP, the prospect of
developing a therapeutically useful kinase inhibitor
seemed daunting, since many enzymes use ATP as a
substrate, and the structure of protein kinases is highly
conserved. Nonetheless, it is now appreciated that kinase
inhibitors have become one of the most successful new
categories of drugs. The story begins with the Abl tyrosine
kinase. BCR-Abl is a fusion protein that results from a
chromosomal translocation (Philadelphia chromo-
some) in patients with chronic myeloid leukemia
(CML) and this kinase seemed to represent an ideal
target, despite the caveats of targeting protein kinases [1].
In fact, the inhibitor imatinib has revolutionized the
treatment of CML with relatively modest side effects [2].
Imatinib was subsequently shown to inhibit several
unrelated tyrosine kinases [3,4]. In fact, these actions led
to imatinib being used successfully in other
Figure 1. Proximal signaling pathways upon stimulation of immune receptors in B and T cells
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Type I and II cytokine receptors associate with Janus kinases (Jaks). Cytokine binding activates Jaks, which then phosphorylate cytokine receptors allowing
STAT (signal transducer and activator of transcription) DNA-binding proteins to attach to receptors and become phosphorylated. STAT activation leads to
their dimerization and translocation to the nucleus where they regulate gene expression. Targets along the signal transduction pathway, including specific
kinase inhibitors, are shown (left). In B cells, antigen ligation leads to activation of three main protein tyrosine kinases (PTKs) — the Src-family kinases Lyn, Syk
and the TEC-family kinase Btk. Syk phosphorylates adaptor protein BLNK and, along with Btk, activates PLC γ. Activation of PLC γ leads to the release of
intracellular Ca
2+ and activation of protein kinase C (PKC), which activate mitogen-activated protein kinases (MAPKs). The MAPK cascade activates
transcription factors nuclear factor-kB (NF-kB) and nuclear factor of activated T cells (NFAT), allowing gene regulation (right). Abbreviations: BLNK: B cell
linker protein; MAPK, mitogen-activated protein kinase; NFAT, nuclear factor of activated T cells; NF-kB, nuclear factor-kB; PLC γ, Phospholipase γ; PIP3K,
phosphatidylinositol triphosphate kinase; PKC, protein kinase C; STAT, signal transducer and activator of transcription; Syk: Spleen tyrosine kinase; DAG,
diacylglycerol; IP3, inositol 1,4,5-triphosphate.
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and the hypereosinophilic syndrome [3,4], by inhibiting
kinases Kit [5] and PDGFR [6]. The success of imatinib
and the epidermal growth factor receptor inhibitors
erlotinib and gefitinib led to the problem of tumors
developing drug resistance associated with mutations
in the targeted kinase [7]. This led to the development
of new multikinase inhibitors such as dasatinib and
sunitinib, which are also now FDA approved [8,9].
Currently, there are several small molecule kinase
inhibitors in routine clinical use, all of which are FDA
approved for oncologic indications (see Table 1).
Targeting cytokine signaling by inhibiting
Janus kinases
The role of cytokines in mediating an immune response
has made them attractive targets for immunomodulatory
drug development. Consequently, monoclonal antibo-
dies against cytokines (e.g. mepolizumab against IL-5)
and cytokine receptors (e.g. tocilizumab against IL-6
receptor), as well as recombinant receptors, have been
used successfully in the clinic [10]. Of note, a large subset
of cytokines (roughly 60), which bind type I/II cytokine
receptors and includes many interleukins, interferons,
colony stimulating factors and other cytokines [11], has a
shared mechanism of signal transduction. The Type I/II
cytokine receptors bind Jaks, which are essential for
signaling [12-14].
The importance in vivo of Jaks was first established by the
identification of patients with immunodeficiency and
JAK3 mutations and by knockout mice.Mutation of JAK3
results in a severe combined immunodeficiency (SCID),
characterized by an almost complete absence of T cells
and NK cells, with defective B cells [15-18]. In contrast
with other Jaks, JAK3 is primarily expressed in hemato-
poieticallyderivedcells, where itisassociated withthe IL-
2 receptor common γ chain (cγc) and mediates signaling
byIL-2,IL-4,IL-7,IL-9,IL-15andIL-21,cytokinesthatare
critical for the development and maturation of T cells
[19]. The profound, but selective, phenotype associated
with JAK3 deficiency led to the suggestion that targeting
Jaks might be a strategy for the development of a new
class of immunomodulatory drugs [20].
JAK inhibitors in the clinic
Tofacitinib
Tofacitinib, formerly designated CP-690,550, was one of
the first JAK inhibitors to enter the clinic. It inhibits JAK3
and JAK1 and, to a lesser extent, JAK2, but has little effect
Table 1. US FDA-approved kinase inhibitors
Agent Targets for therapeutic activity US FDA-approved indication
Direct kinase inhibitors by competing for the ATP-binding pocket
Imatinib BCR–ABL, PDGFR and KIT CML and GIST
Dasatinib BCR–ABL CML
Nilotinib BCR–ABL CML
Gefitinib EGFR Non-small cell lung cancer
Erlotinib EGFR Non-small cell lung cancer and pancreatic cancer
Lapatinib EGFR and ERBB2 Breast cancer
Sunitinib VEGFR2, PDGFR and KIT Renal cell carcinoma, GIST, pancreatic cancer
Sorafenib VEGFR2 and PDGFR Renal cell carcinoma and hepatocellular carcinoma
Pazopanib VEGFR2, PDGFR and KIT Renal cell carcinoma
Crizotinib ALK/c-MET Non-small cell lung cancer
Vemurafenib BRAF Melanoma
Vandetanib VEGFR-2, EGFR, RET and ErbB-1 Medullary thyroid cancer
Ruxolitinib JAK1/JAK2 Myelofibrosis
Indirect kinase inhibitors by binding to FK506 binding protein 12 (FKBP12)
Sirolimus mTOR Solid organ and bone marrow transplantation
Everolimus mTOR Renal cell carcinoma, Subependymal Giant Cell
Astrocytoma (SEGA) associated with Tuberous
Sclerosis (TS) and Progressive Neuroendocrine
Tumors of Pancreatic Origin (PNET)
Temsirolimus mTOR Renal cell carcinoma
Monoclonal antibodies binding to receptor tyrosine kinases
Trastuzumab ERBB2 Breast cancer
Cetuximab EGFR Colorectal cancer, and squamous carcinoma of
head and neck
Panitumumab EGFR Colorectal cancer
Bevacizumab VEGF Colorectal cancer, non-small cell lung cancer,
breast cancers, glioblastoma and renal cell
carcinoma
Abbreviations: CML, chronic myeloid leukemia; EGFR, epidermal growth factor receptor; FDA, Food and Drug Administration; GIST, gastrointestinal
stromal tumor; PDGFR, platelet-derived growth factor receptor; VEGFR2, vascular endothelial growth factor receptor 2.
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inhibits cγc cytokines but also blocks IFN-γ,I L - 6a n d ,t oa
lesser extent, IL-12 and IL-23. Functionally, tofacitinib
affects both innate and adaptive immune responses by
inhibiting pathogenic Th17 cells and Th1 and Th2 cell
differentiation [13]. In Phase II trials in rheumatoid
arthritis, tofacitinib as monotherapy met the American
College of Rheumatology 20% improvement (ACR20)
criteria in 61-70% of patients at doses between 5 and
15 mg twice daily [22]. These results were replicated in
phase III trials at doses 5 and 10 mg twice daily [23]. In
combination with methotrexate, tofacitinib met its
primary endpoint (pre-agreed measure of success) in a
highly active disease group [24,25]. Additionally, tofaciti-
nib significantly reduced progression of structural damage
compared with placebo in patients with active rheumatoid
arthritis on methotrexate [26]. Tofacitinib was also found
to be beneficial in patients with rheumatoid arthritis who
were refractory to biologics [27]. Tofacitinib is also under
clinical investigation for psoriasis, inflammatory bowel
disease and prevention of transplant rejection.
The major adverse effects of tofacitinib include increased
incidence of infections and increased low density
lipoprotein levels; however, the incidence of infection
with opportunistic organisms appears to be limited [28].
The former is perhaps expected given the roles of diverse
cytokines in host defense. The latter is likely related to
inhibition of IL-6 signaling [29]. Anemia and neutrope-
nia were also reported [30], presumably related to JAK2
inhibition and interference with cytokines, such as
erythropoietin and colony stimulating factors [31]. Little
reduction in CD4
+ T cells has been seen, but significant
reduction in NK cells and CD8
+ T cells does occur, with
an as yet undetermined infection risk [32,33]. Thus, the
major adverse effects of tofacitinib appear to be
consequences of blocking cytokine signaling as one
might expect, and seemingly not related to off-target
effects. The balance of efficacy and safety of tofacitinib
compared to standard of care therapy will need to be
ascertained in clinical trials and, if approved, ultimately
in the routine clinical use of these drugs.
VX-509
VX-509 is another inhibitor designed to selectively
inhibit Jak3. A phase IIa study has just been completed
and, like tofacitinib, use of VX-509 was also associated
with a dose-dependent increase in clinical response in
rheumatoid arthritis.
GLPG0634
The results of a Phase II trial of a selective Jak1 inhibitor
GLPG0634 have also been released, and it too is
efficacious and causes no unexpected adverse advents.
Ruxolitinib
As gene targeting of either Jak1 or Jak2 in mice was
embryonically lethal, it was thought that pharmacologi-
cal inhibition might be problematic. However, the
discovery that JAK2 gain-of-function mutations underlie
polycythemia vera and myelofibrosis provided the
impetus to purposely target JAK2. This led to the
development of the drug, ruxolitinib, which blocks
JAK1 and JAK2. In a phase II study, patients receiving
ruxolitinib for myelofibrosis showed significant clinical
improvement. Despite the drug’s ability to block both
JAK1 and JAK2, it was well tolerated [34]. In addition,
efficacy was seen in patients that did not exhibit JAK2
mutations, suggesting that the drug might be affecting
kinases other than JAK2. This drug was recently approved
by the FDA for treatment of myelofibrosis.
As cγc cytokines employ both JAK1 and JAK3 for
signaling, ruxolitinib and tofacitinib will block many
of the same cytokines. It is therefore of interest to note
that, in a phase II study in rheumatoid arthritis,
ruxolinitib had efficacy that was not dissimilar from
tofacitinib [35].
INCB028050
Another selective JAK1 and JAK2 inhibitor, INCB028050,
showed dose-dependent efficacy in active rheumatoid
arthritis patients refractory to disease-modifying drugs
and biologics, with the most frequent side effects being
headache, upper respiratory infections and diarrhea
[36].
Other JAK inhibitors
Other JAK inhibitors are also in development and clinical
trials for oncologic [37-49] and autoimmune indications
[50] are ongoing (see Table 2). The comparative efficacy
and toxicity of the various JAK inhibitors will be
important to follow in longer-term studies.
Targeting other kinases
Despite their scientific appeal, multiple attempts to
generate clinically useful p38 MAPK inhibitors have
generally failed, either due to toxicity or inadequate
efficacy. Only one compound, VX-702, yielded a modest
effect on clinical signs and symptoms in rheumatoid
arthritis and a transient effect on biomarkers of
inflammation [51].
Zap70 or Syk mediate signals from receptors that contain
immunoreceptortyrosine-basedmotifs(ITAMs)(Figure1).
Like JAK3, Zap70 deficiency also causes SCID, but in this
c a s et h e r ei sp r e f e r e n t i a ll o s so fC D 8 +Tc e l l s[ 5 2 ] .F o rt h i s
reason,Zap70isarationaltarget;unfortunately,aclinically
useful compound has not emerged. In contrast, the Syk
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in a Phase II study in rheumatoid arthritis [53]. Fostama-
tinib also targets FLT3, KIT, LCK among other kinases,
possibly contributing to its clinical benefit [54]. Toxicities
include diarrhea, infections, neutropenia and hyperten-
sion. A subsequent study, involving patients refractory to
biologics,failedtomeetitsprimaryendpoint;however,this
was attributed to study design issues [55]. Because of its
critical role in B cell function, another logical target is Tec
family member Btk. Such inhibitors are first being used in
the setting of B cell lymphoma, but could be useful in
autoimmune diseases as well.
Members of the PKC family are activated downstream of
a variety of key immunologic receptors. One PKC
inhibitor, sotrastaurin, has been tested in kidney
allograft rejection, and showed moderate efficacy but
less nephrotoxicity compared with calcineurin inhibitor
regimens [56]. Phase I and II trials on inflammatory
bowel disease, psoriasis [57] and Diffuse Large B-Cell
Lymphoma are ongoing.
Colony stimulating factor 1 receptor (c-Fms) is a
transmembrane receptor tyrosine kinase. A phase 1 trial
of a CSF1R inhibitor (PLX5622) in rheumatoid arthritis
is ongoing.
Conclusions and future prospects
The last few years have produced great advances in
deciphering the mechanisms involved in intracellular
signaling pathways. Consequently, our understanding of
the molecular basis of immune cell activation is vastly
more sophisticated. These advances have been associated
with the identification of effective, safe kinase inhibitors.
Many of these agents were developed for the treatment of
cancer, and the pleiotropic effects of kinase inhibitors,
initially thought of as a disadvantage, have proved to be
beneficial. The use of kinase inhibitors has expanded
beyond malignancies to autoimmune diseases with
favourable safety profile. Also, multikinase inhibitors
that have broad effects have been less problematic than
one might have envisioned, but it is too early for us to
know how useful such inhibitors will be in the treatment
of immune-mediated disease. Highly selective kinase
inhibitors, such as p38 MAPK inhibitors, have been
disappointing in the treatment of autoimmune diseases,
either due to toxicity and/or lack of efficacy. Whether
broad spectrum, multi-kinase inhibitors or highly
selective second and third generation kinase inhibitors
will ultimately be more efficacious and safe remains to
be established. The issue of acquired resistance, while a
very real problem in oncology, presumably will not be a
major issue in autoimmune diseases.
Table 2. Kinase inhibitors in development for autoimmunity
Agent Targets for therapeutic activity Indication/Phase
Tofacitinib JAK3/JAK1/JAK2 RA/Phase III
Psoriasis/Phase II
IBD/Phase II
VX-509 JAK3 RA/Phase II
R-348 JAK3 RA/Phase I
Ruxolitinib JAK1/JAK2 Psoriasis/Phase II
INCB-028050 JAK1/JAK2 RA/Phase II
GLPG-0634 JAK1/JAK2/TYK2 RA/Phase II
AC-430 JAK2 RA/Phase I
Lymphoma/Phase I
Lestaurtinib FLT3/TrkA/JAK2 AML/Phase III
Psoriasis/Phase II
Pancreatic cancer/Phase II
Fostamatinib Syk/FLT3/KIT/LCK RA/Phase III
NHL/Phase I/II
CLL/Phase I/II
ACU-XSP-001 Syk Asthma/Phase II
R-343 Syk Asthma/Phase I
PRT-062607 Syk RA/Phase I
CLL/Phase I
NHL/Phase I
Sotrastaurin (AEB071) PKC Psoriasis/Phase II
IBD/Phase II
Solid organ transplantation/Phase II
Diffuse Large B-Cell Lymphoma/Phase I
PLX 5622 CSF1R (Fms) RA/Phase I
Abbreviations: ACU-XSP-001, small interfering RNA that silences Syk gene; CLL, chronic lymphoid leukemia; CSF1, colony stimulating factor 1 receptor;
FLT3, ms-related tyrosine kinase 3; NHL, non-Hodgkin lymphoma; PKC, protein kinase C; TrkA, aka high affinity nerve growth factor receptor or
neurotrophic tyrosine kinase receptor type 1 or TRK1-transforming tyrosine kinase protein.
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development of many more immunosuppressants that
inhibit kinases expressed in immune cells. It will also not
be a surprise if many drugs that enter clinical use as
treatments for cancer are found to be efficacious in the
treatment of autoimmune disease or transplant rejection.
There is ample precedent for this with drugs such as
cyclophosphamide, azathioprine and methotrexate. It
also bears pointing out that not all kinase inhibitors exert
their effect by competing for ATP in the kinase domain. A
prime example is the drug rapamycin (also called
sirolimus), as an approved immunosuppressant effective
for allograft rejection and graft versus host disease [58-
61]. It binds FK binding protein 12 and mammalian
target of rapamycin (mTOR) complex 1 and indirectly
inhibits the kinase mTOR [62-65], a kinase that is
activated by a number of growth factor receptors and
cytokines [66]. Thus, indirectly inhibiting kinases by
targeting their associated complexes is another effective
strategy for developing drugs. Regardless, the number of
kinase inhibitors and the range of clinical indications are
likely to expand dramatically in the next few years.
Precisely how these drugs are used in combination with
or in place of other therapies such as biologics, steroids,
etc. remains to be determined.
Abbreviations
TCR, T cell receptor; BCR, B cell receptor; NK, natural
killer; PKC, protein kinase C; JAK, Janus kinase; IL,
interleukin; TNF, tumor necrosis factor; CML, chronic
myeloid leukemia; SCID, severe combined immunode-
ficiency; MAPK, mitogen-activated protein kinase; Syk,
spleen tyrosine kinase; ITAMs, immunoreceptor tyrosine
based motifs; mTOR, mammalian target of rapamycin.
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